Last Updated: April 14, 2026
Nootropic peptides are short-chain neurotrophic signaling compounds used in preclinical research to investigate cognition, memory consolidation, stress response, and neuroprotection. Unlike classical small-molecule nootropics, peptides such as Selank, Semax, and ARA-290 act on endogenous neuropeptide pathways, regulating BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and innate repair receptor signaling. Selank is a heptapeptide tuftsin analog studied for anxiolytic activity without sedation. Semax is a seven-amino-acid ACTH(4-10) fragment investigated for its BDNF/NGF-modulating properties, with no reported hormonal activity. ARA-290 is an 11-amino-acid erythropoietin-derived peptide targeting the heteromeric innate repair receptor (IRR, EPOR/βcR), researched for neuroprotection and small-fiber nerve signaling. This guide synthesizes published studies suggesting distinct mechanisms and preclinical research applications for each compound. All three peptides are intended exclusively for laboratory use and are not for human or animal consumption.
Quick Comparison: Selank, Semax, and ARA-290
| Peptide | Parent Molecule | Primary Mechanism | Research Focus | Physical Form |
|---|---|---|---|---|
| Selank | Tuftsin (immunopeptide) | GABAergic modulation, enkephalin stabilization | Anxiety models, immunomodulation | Lyophilized powder, 5 mg |
| Semax | ACTH(4-10) fragment | BDNF/NGF upregulation, melanocortin signaling | Memory consolidation, neuroprotection | Lyophilized powder, 10 mg |
| ARA-290 | Erythropoietin helix B | Innate repair receptor (IRR/βcR) agonism | Neuropathy, tissue repair signaling | Lyophilized powder, 10 mg |
What Are Nootropic Peptides?
Nootropic peptides are short amino acid sequences that modulate central nervous system signaling pathways implicated in cognition, mood regulation, and neuronal resilience. Preclinical research indicates that this class acts primarily through three overlapping mechanisms: neurotrophic factor upregulation (BDNF, NGF, GDNF), neuropeptide receptor modulation (melanocortin, enkephalin, tuftsin pathways), and cytokine-adjacent receptor signaling (innate repair receptor, or IRR). Because peptides are composed of naturally occurring amino acids, they are typically rapidly hydrolyzed by peripheral peptidases — a pharmacokinetic profile that has directed much preclinical investigation toward intranasal and subcutaneous delivery routes in animal models.
The nootropic peptide category is anchored by three Russian-developed heptapeptides — Selank and Semax — alongside ARA-290, a non-erythropoietic fragment of human erythropoietin developed by Araim Pharmaceuticals. Published studies in animal cognition and electrophysiology paradigms suggest differential effects on BDNF expression, enkephalinase inhibition, and hippocampal plasticity. Research interest has expanded because these peptides display favorable preclinical safety profiles and appear to activate endogenous signaling rather than introducing novel pharmacology. This makes them attractive tools for probing the neurotrophic basis of learning, memory, and stress resilience in laboratory settings.
Neurotrophic Signaling: BDNF, NGF, and the IRR Pathway
BDNF is a member of the neurotrophin family critical for long-term potentiation (LTP) and synaptic plasticity in hippocampal circuits. NGF supports cholinergic neurons in the basal forebrain and peripheral sympathetic systems. The innate repair receptor (IRR) — a heterodimer of the EPO receptor and the common beta receptor (CD131) — is expressed on injured or stressed tissue and mediates tissue-protective signaling distinct from hematopoietic EPO activity. Selank and Semax have been reported in preclinical research to upregulate BDNF mRNA in hippocampal tissue; ARA-290 selectively engages the IRR without triggering erythropoiesis, which is why it is described as non-hematopoietic in the literature.
Why Peptides Rather Than Small Molecules?
Classical nootropic research has historically focused on small molecules — racetams, cholinergic agonists, and ampakines — that cross the blood-brain barrier readily and act on well-characterized neurotransmitter receptors. Peptide-based nootropics offer a complementary approach. Because peptides derive from or mimic endogenous signaling molecules, they engage pathways that are already calibrated by physiological feedback loops, potentially producing more targeted and self-limiting effects in preclinical models. The amino-acid composition of Selank, Semax, and ARA-290 also means that degradation products are standard amino acids, simplifying metabolite analysis in research toxicology studies.
Preclinical research indicates that stabilizing peptide extensions — such as the proline-glycine-proline tail on Selank and Semax — meaningfully extend half-life by resisting aminopeptidase and carboxypeptidase cleavage. This pharmacokinetic tuning is a recurring theme in neuropeptide research and shapes the comparative literature on dose-response and timing of action in rodent cognition assays. Laboratory investigators selecting nootropic peptides for a study should carefully review the published pharmacokinetic data for each candidate, as bioavailability and brain penetration differ substantially across administration routes.
How Does Selank Work as a Tuftsin Derivative?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Russian Academy of Medical Sciences as a stabilized analog of the endogenous immunopeptide tuftsin. The proline-glycine-proline tripeptide added to the carboxyl terminus extends plasma half-life relative to native tuftsin, which is degraded within minutes. Preclinical research indicates that Selank exerts anxiolytic-like activity in rodent elevated plus-maze and open-field paradigms without the sedation, motor impairment, or dependence liability associated with benzodiazepine GABAA positive allosteric modulators.
Published studies suggest Selank’s anxiolytic mechanism is mediated in part through modulation of GABAergic tone, inhibition of enkephalin-degrading enzymes (thereby prolonging endogenous enkephalin activity), and alteration of serotonin metabolism in limbic regions. Research on Selank has also reported immunomodulatory effects — consistent with its tuftsin heritage — including normalization of cytokine balance and interferon stabilization in animal models of immune dysregulation. Laboratory investigations have additionally examined Selank’s effect on BDNF expression in hippocampal tissue, with several studies reporting upregulation following intranasal administration in rodents.
In research protocols, Selank is supplied as a lyophilized powder intended to be reconstituted for laboratory use only. Its favorable preclinical safety profile and lack of reported withdrawal phenomena make it a frequently referenced compound in comparative anxiolytic peptide studies. Investigators examining stress-related cognition, cytokine-behavior interactions, or enkephalinergic signaling often include Selank as a reference compound alongside Semax and other neuropeptides. Product details are available on the Selank 5mg research page.
What Is Semax’s Mechanism as an ACTH Fragment?
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) corresponding to the 4-7 sequence of adrenocorticotropic hormone (ACTH) with a stabilizing Pro-Gly-Pro extension. Critically, preclinical research indicates Semax retains the neurotropic activity of the ACTH(4-10) fragment without the hormonal (corticotropic) effects of full-length ACTH — meaning no measurable stimulation of adrenal cortisol release in animal studies. This separation of neurotrophic from hormonal activity is central to its research profile.
Published studies suggest Semax acts through multiple overlapping pathways. Melanocortin receptors (MC4R in particular) appear to mediate a subset of its CNS effects, while dopaminergic and serotonergic systems are secondarily modulated. A prominent finding across preclinical research is Semax’s capacity to upregulate BDNF and NGF expression in the hippocampus and basal forebrain following intranasal administration in rodents. Transcriptomic studies have reported changes in gene expression related to neurogenesis, synaptic plasticity, and the immediate-early gene response. Semax has also been investigated in rodent models of cerebral ischemia, where preclinical research indicates a neuroprotective effect associated with reduced infarct volume and preserved cognitive performance in behavioral assays.
Research protocols examining learning, attention, and memory consolidation frequently cite Semax for its consistent effect on BDNF signaling. Because it is an ACTH(4-7) analog rather than a full melanocortin agonist, it is often paired with selective MC4R ligands to dissect melanocortin-dependent from BDNF-dependent effects in laboratory settings. Semax is supplied as a lyophilized powder for reconstitution and laboratory use only; it is not for human or animal consumption. Investigators reviewing cognition-related neurotrophic peptides commonly consult the Semax 10mg research page for lot and purity documentation.
How Does ARA-290 Provide Neuroprotection?
ARA-290 — also known as cibinetide — is an 11-amino-acid linear peptide (pyroglutamate-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) derived from the spatial configuration of helix B of human erythropoietin. Where native EPO engages the classical homodimeric EPO receptor (EPOR2) to drive erythropoiesis, ARA-290 selectively binds the heteromeric innate repair receptor (IRR) — a complex of the EPO receptor and the common beta subunit CD131 (βcR) expressed on injured tissue. Preclinical research indicates this selectivity allows ARA-290 to activate tissue-protective signaling without stimulating red blood cell production, which is why it is classified in the literature as non-hematopoietic.
Published studies suggest ARA-290 engagement of the IRR triggers downstream activation of PI3K/Akt, JAK2, and STAT pathways associated with anti-apoptotic and anti-inflammatory signaling. Preclinical research has investigated ARA-290 in rodent models of small-fiber neuropathy, ischemia-reperfusion injury, diabetic corneal nerve compromise, and sarcoidosis-related neuropathy. Outcomes reported in these laboratory models include preserved epidermal nerve fiber density, reduced inflammatory cytokine expression, and improved functional assays. Because IRR expression is upregulated in stressed or inflamed tissue, ARA-290 effects are typically observed only in compromised tissue — an important consideration in research design and control selection.
In research protocols, ARA-290 is supplied as a lyophilized powder to be reconstituted for laboratory use. Its non-hematopoietic profile makes it valuable for investigations dissecting tissue-protective EPO signaling from erythropoiesis, and for comparative work against first-generation EPO analogs. Laboratory investigators examining neuropathy models, IRR pharmacology, or cytoprotective signaling cascades reference ARA-290 alongside related innate repair peptides. Additional product and reference information is available on the ARA-290 10mg research page.
Comparative Pharmacokinetics
The three peptides differ meaningfully in plasma half-life and tissue distribution, which shapes how each is used in research protocols. Selank and Semax, following intranasal administration in rodents, are reported in preclinical research to reach CNS tissue within minutes, with functional effects observed over a 1-4 hour window and tapering thereafter. The proline-glycine-proline carboxyl extension on both molecules confers resistance to peripheral peptidases but does not prevent brain-region-specific catabolism. ARA-290, by contrast, has a short circulating half-life (reported in the literature at approximately 2 minutes after IV administration in animal studies) yet produces durable tissue-protective effects, consistent with IRR engagement triggering sustained intracellular signaling cascades. This decoupling of pharmacokinetic exposure from pharmacodynamic effect is a recurring feature of IRR agonists in preclinical research and is an important consideration when designing dosing schedules for laboratory use.
How Do These Peptides Compare for Cognitive Research?
Selank, Semax, and ARA-290 occupy distinct pharmacological niches within the nootropic peptide category, and research design should match the peptide to the mechanism under investigation. The decision matrix below summarizes common preclinical research objectives and the peptide most frequently cited in the relevant literature.
| Research Objective | Best-Matched Peptide | Rationale |
|---|---|---|
| Anxiety-related behavioral models | Selank | Anxiolytic activity in rodent paradigms without sedation or dependence signals |
| BDNF/NGF upregulation studies | Semax | Consistent preclinical findings of hippocampal BDNF/NGF expression changes |
| Memory consolidation & LTP | Semax | Published studies suggest effects on hippocampal plasticity and learning assays |
| Cytokine / immunomodulation overlap | Selank | Tuftsin heritage and reported cytokine-normalizing effects in animal models |
| Small-fiber neuropathy models | ARA-290 | IRR-selective, non-hematopoietic EPO-derived signaling on injured nerves |
| Ischemia / reperfusion injury | ARA-290 or Semax | Both cited in preclinical stroke/ischemia literature via distinct mechanisms |
| Enkephalinergic pathway probes | Selank | Reported inhibition of enkephalin-degrading enzymes prolongs endogenous activity |
| IRR / CD131 receptor pharmacology | ARA-290 | Prototype non-hematopoietic IRR agonist; selective for injured-tissue receptor complex |
Study design should also account for delivery route, stability, and control peptides. Selank and Semax are commonly investigated via intranasal administration in rodents, which bypasses first-pass metabolism and provides direct nose-to-brain access along olfactory and trigeminal pathways. ARA-290 in preclinical research is more commonly administered subcutaneously, consistent with its systemic tissue-protective signaling profile. Reconstitution buffer selection (bacteriostatic vs sterile water), peptide concentration, and storage conditions (2-8 °C post-reconstitution; -20 °C lyophilized) all materially affect potency in laboratory use.
Experimental Design Considerations
Beyond peptide selection, rigorous preclinical research with nootropic peptides requires careful attention to control conditions. Vehicle-only controls must match the reconstitution buffer exactly, because bacteriostatic water contains benzyl alcohol, which has documented effects on certain cellular assays. Timing of administration relative to behavioral testing also matters: Selank and Semax are typically dosed 15-30 minutes before a behavioral task in rodent research, consistent with their rapid peak after intranasal delivery. ARA-290 protocols more often involve daily dosing over days to weeks, reflecting its role in tissue-protective signaling that accumulates with repeated IRR engagement.
Published studies suggest that sex, strain, and baseline stress of the research animal meaningfully influence outcomes in nootropic peptide paradigms. Hippocampal BDNF response to Semax, for example, has been reported to differ across rat strains, and anxiolytic outcomes with Selank in mice are known to be modulated by baseline anxiety phenotype. Investigators planning comparative studies should standardize housing conditions, handling protocols, and circadian timing of administration. Where possible, blinded scoring of behavioral outcomes and pre-registration of primary endpoints further strengthen the rigor of peptide research and aid reproducibility across laboratories.
Purity, Sourcing, and Reference Standards
The reproducibility of nootropic peptide research depends heavily on the purity and identity verification of the compound being studied. High-performance liquid chromatography (HPLC) analysis reporting purity of at least 98%, accompanied by mass spectrometry confirming the expected molecular mass, is the minimum documentation expected in peer-reviewed preclinical literature. Certificates of analysis (COAs) accompanying each lot allow investigators to cross-reference purity, endotoxin levels (for injectable route research), and counter-ion content — the last of which affects peptide mass per milligram and therefore dose calculations in laboratory protocols.
For investigators referencing Selank, Semax, and ARA-290 in comparative research, lot-to-lot consistency is particularly important. Small variations in purity or counter-ion content can shift effective dose by 5-10%, which is significant in dose-response studies and can contribute to variance across independent laboratories. When published studies are replicated, reporting the specific lot, supplier, and COA metadata alongside the sequence and mass is best practice. All peptides discussed in this guide are supplied as research-grade lyophilized material intended strictly for laboratory use.
Summary of Mechanistic Differences
To synthesize the mechanism sections: Selank operates predominantly at the interface of GABAergic, enkephalinergic, and immunomodulatory signaling, making it the reference compound for anxiety-adjacent behavioral and cytokine research in rodent paradigms. Semax engages melanocortin receptors and drives BDNF/NGF upregulation, positioning it as the nootropic peptide most frequently cited in neurotrophic and memory consolidation studies. ARA-290 is mechanistically distinct from both: it bypasses neurotransmitter pharmacology entirely and instead activates a tissue-state-dependent cytoprotective receptor that is only meaningfully expressed in stressed or injured tissue. Research investigators who appreciate these distinctions are best positioned to design experiments that isolate the pathway of interest and select the appropriate comparator peptide. Published studies suggest that pairing a neurotrophic peptide with an IRR agonist in parallel arms can help discriminate between BDNF-dependent and IRR-dependent components of neuroprotection in ischemia or neuropathy models.
Frequently Asked Questions
What distinguishes Selank from Semax in research protocols?
Selank and Semax are both Russian-developed heptapeptides with a proline-glycine-proline stabilizing extension, but they derive from unrelated parent molecules and operate through different mechanisms. Selank is a tuftsin analog (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with preclinical research indicating anxiolytic activity via GABAergic modulation, enkephalinase inhibition, and immunomodulation consistent with its tuftsin heritage. Semax is an ACTH(4-7) fragment analog (Met-Glu-His-Phe-Pro-Gly-Pro) with published studies suggesting robust BDNF and NGF upregulation and effects on memory consolidation without corticotropic activity. In research design terms, Selank is typically the reference compound for anxiety-related behavioral models and cytokine-behavior studies, while Semax is the reference for neurotrophin-dependent learning, memory, and neuroprotection paradigms. Both are supplied as lyophilized powders for laboratory use only.
Why is ARA-290 considered non-hematopoietic?
ARA-290 is described as non-hematopoietic because it does not activate the classical homodimeric erythropoietin receptor (EPOR2) that drives red blood cell production. Instead, preclinical research indicates ARA-290 selectively binds the innate repair receptor (IRR), a heterodimer composed of the EPO receptor and the common beta receptor subunit CD131 (βcR). The IRR is expressed predominantly on stressed, injured, or inflamed tissue, while the homodimeric EPOR2 is expressed on erythroid progenitors in bone marrow. Because ARA-290 corresponds to the helix B surface of erythropoietin — a region that engages the IRR but not the erythropoietic receptor complex — it activates tissue-protective signaling cascades (PI3K/Akt, JAK2, STAT) without stimulating erythropoiesis. This selectivity is central to its research utility for probing EPO-derived cytoprotection independent of hematologic effects. Laboratory use only.
Are nootropic peptides oral or injected in research?
In preclinical research, nootropic peptides are rarely administered orally because peptides composed of L-amino acids are rapidly hydrolyzed by gastric and intestinal peptidases, resulting in poor bioavailability. For Selank and Semax, intranasal administration is the most commonly reported route in published studies, as it leverages nose-to-brain transport along olfactory and trigeminal pathways while bypassing first-pass hepatic metabolism. ARA-290 in preclinical research is more frequently administered subcutaneously, consistent with its systemic IRR-mediated tissue-protective profile. In laboratory settings, research protocols reconstitute lyophilized peptide in bacteriostatic or sterile water, aliquot to working concentration, and store at 2-8 °C (reconstituted) or -20 °C (lyophilized). These compounds are intended exclusively for laboratory and research purposes and are not for human or animal consumption.
What does BDNF have to do with nootropic peptide research?
Brain-derived neurotrophic factor (BDNF) is a neurotrophin essential for long-term potentiation, hippocampal synaptic plasticity, and neuronal survival, and it has become a central biomarker in nootropic peptide research. Published studies suggest both Selank and — more prominently — Semax upregulate BDNF mRNA and protein expression in the hippocampus following intranasal administration in rodents. This BDNF signature is significant because hippocampal BDNF is mechanistically linked to learning and memory in preclinical paradigms such as Morris water maze, passive avoidance, and novel object recognition. Researchers investigating the neurotrophic basis of cognition often measure BDNF as a readout of peptide engagement alongside behavioral assays. NGF (nerve growth factor) plays a parallel role in cholinergic basal forebrain circuits and is similarly referenced in Semax research. All such investigations remain within preclinical laboratory scope.
What is the innate repair receptor (IRR) and why does it matter?
The innate repair receptor (IRR) is a heteromeric cell-surface receptor composed of the erythropoietin receptor and the common beta receptor subunit CD131 (βcR). Unlike the homodimeric EPOR2 that drives erythropoiesis on bone marrow progenitors, the IRR is expressed predominantly on tissue that is stressed, injured, or inflamed — including neurons, cardiomyocytes, renal tubular cells, and immune cells. Preclinical research indicates IRR engagement activates tissue-protective and anti-inflammatory signaling cascades (PI3K/Akt, JAK2, STAT) without stimulating red blood cell production. ARA-290 is the prototype selective IRR agonist, corresponding to helix B of erythropoietin. Its IRR selectivity makes it a valuable research tool for dissecting tissue-protective EPO signaling from hematopoietic EPO signaling — a distinction that was historically obscured when only full-length EPO was available. This mechanism underlies ARA-290’s role in neuropathy and ischemia research.
How should research peptides be stored and reconstituted?
Lyophilized nootropic peptides should be stored at -20 °C in a sealed, desiccated container to maintain long-term stability; published stability studies suggest lyophilized peptides retain potency for extended periods under these conditions. To reconstitute for research, investigators typically use bacteriostatic water (containing 0.9% benzyl alcohol) or sterile water for injection, added slowly down the side of the vial to avoid foaming or denaturation. After reconstitution, peptides should be stored at 2-8 °C and used within a validated stability window — commonly cited as 2-4 weeks for most short peptides, though specific peptides vary. Freeze-thaw cycles should be minimized; aliquoting the reconstituted solution is standard laboratory practice. Working concentration, buffer, and route of administration must match the published protocol being referenced. All procedures are intended for laboratory use only; these peptides are not for human or animal consumption.
All products are intended for laboratory and research purposes only. Not for human or animal consumption. These statements have not been evaluated by the FDA.